Integrins in breast cancer dormancy.
Among breast cancer patients, 20% to 45% develop malignant lesions following their initial treatment. This relapse may occur after an apparent remission period that can range from years to several decades. Clinical observations suggest that breast-derived malignant cells have the ability to survive subclinically for a very long period of time before eventually resuming proliferation and forming detectable lesions. While the precise molecular events that correspond to this dormant phenotype remain poorly understood, data published during the last 10 years have underlined an important role of integrin proteins in the regulation of this phenomenon.
Department of Biochemistry, Faculty of Medicine, McGill University, Montreal, Canada.
Stephanie M
SM
Pontier
William J
WJ
Muller
D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology* / Q000503:physiopathology*; D002470:Cell Survival; D005260:Female; D006801:Humans; D016023:Integrins / Q000502:physiology*; D008954:Models, Biological; D014411:Neoplastic Stem Cells / Q000473:pathology / Q000502:physiology; D009857:Oncogenes; D012008:Recurrence; D013997:Time Factors
D016023:Integrins